Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Drug Development for Select Diseases

View through CrossRef
Background: Central Council for Research in Ayurvedic Sciences (CCRAS) is actively involved in the scientific process of drug development adopting prevalent guidelines such as good clinical practices guidelines for Ayurveda, Siddha, Unani (ASU) drugs (GCP-ASU), Ministry of AYUSH and National ethical guidelines for Bio-medical Research (ICMR), WHO guidelines for traditional medicines, etc. Drug developed: Till date, 11 technologies have been developed and commercialized by transferring to the Industry through National Research Development Corporation (NRDC), Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India, for wider public utility including drugs for disease like AYUSH 82 for diabetes, AYUSH-64 for malaria, AYUSH SG for rheumatoid arthritis etc, also 17 drugs for RCH have been developed. Drug development under progress: Various new formulations like AYUSH manas for mental retardation/cognitive deficit, AYUSH QOL 2C for improving quality of life in cancer patients, AYUSH Rasayana (A and B) for Geriatric health, AYUSH C1 oil for wound healing, AYUSH PJ-7 for dengue, AYUSH M-3 for migraine, AYUSH SL for filariasis, AYUSH A for bronchial asthma, AYUSH D for Type II diabetes mellitus, carctol S for ovarian cancer, AYUSH K1 for chronic kidney diseases, AYUSH GMH for non alcoholic fatty liver disease (NAFLD) and AYUSH PTK for hepato-protection as adjuvant to anti tubercular treatment (ATT) have been taken up which are at different phases of drug development. Conclusion: Council is working towards drug development following scientific lines taking leads from LHTs and from classical Ayurveda texts to bring out scientifically validated medicine for use among masses in disease conditions of National importance and is committed to develop and provide treatment and prevention of emerging important lifestyle-related disease and other health requirements.
Title: Drug Development for Select Diseases
Description:
Background: Central Council for Research in Ayurvedic Sciences (CCRAS) is actively involved in the scientific process of drug development adopting prevalent guidelines such as good clinical practices guidelines for Ayurveda, Siddha, Unani (ASU) drugs (GCP-ASU), Ministry of AYUSH and National ethical guidelines for Bio-medical Research (ICMR), WHO guidelines for traditional medicines, etc.
Drug developed: Till date, 11 technologies have been developed and commercialized by transferring to the Industry through National Research Development Corporation (NRDC), Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India, for wider public utility including drugs for disease like AYUSH 82 for diabetes, AYUSH-64 for malaria, AYUSH SG for rheumatoid arthritis etc, also 17 drugs for RCH have been developed.
Drug development under progress: Various new formulations like AYUSH manas for mental retardation/cognitive deficit, AYUSH QOL 2C for improving quality of life in cancer patients, AYUSH Rasayana (A and B) for Geriatric health, AYUSH C1 oil for wound healing, AYUSH PJ-7 for dengue, AYUSH M-3 for migraine, AYUSH SL for filariasis, AYUSH A for bronchial asthma, AYUSH D for Type II diabetes mellitus, carctol S for ovarian cancer, AYUSH K1 for chronic kidney diseases, AYUSH GMH for non alcoholic fatty liver disease (NAFLD) and AYUSH PTK for hepato-protection as adjuvant to anti tubercular treatment (ATT) have been taken up which are at different phases of drug development.
Conclusion: Council is working towards drug development following scientific lines taking leads from LHTs and from classical Ayurveda texts to bring out scientifically validated medicine for use among masses in disease conditions of National importance and is committed to develop and provide treatment and prevention of emerging important lifestyle-related disease and other health requirements.

Related Results

Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Diverse mutant selection windows shape spatial heterogeneity in evolving populations
Diverse mutant selection windows shape spatial heterogeneity in evolving populations
ABSTRACTMutant selection windows (MSWs), the range of drug concentrations that select for drug-resistant mutants, have long been used as a model for predicting drug resistance and ...
A Review on Recent Rational Approaches to Drug Design, Development and Its Discovery
A Review on Recent Rational Approaches to Drug Design, Development and Its Discovery
The steps involved in drug design, drug development and drug discovery are highly expensive, extremely challenging and  time  consuming.  Although  the  drug  designing,  process  ...
Drug-Drug-Dietary interactions in pharmacotherapy of GIT medication: A review
Drug-Drug-Dietary interactions in pharmacotherapy of GIT medication: A review
Successful drug therapy depends on the interaction between drug-drug and drug-diet. Drug interactions are a vital reason for causing adverse drug reactions and modify one drug effe...
Study Of Drug Interaction in Diabetes Mellitus Therapy at the Inpatient Installation of Al Islam Hospital Bandung
Study Of Drug Interaction in Diabetes Mellitus Therapy at the Inpatient Installation of Al Islam Hospital Bandung
The patient's clinical outcome can be influenced by drug related problems, one of  which is drug interactions, because the more complex the therapy carried out, it will be in line ...

Back to Top